Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia

New England Journal of Medicine

Volumn 377, Issue 7, 2017, Pages 613-622

  Rolnik, Daniel L ^a   Wright, David ^e   Poon, Liona C ^h   O’Gorman, Neil ^a   Syngelaki, Argyro ^a   De Paco Matallana, Catalina ⁱ   Akolekar, Ranjit ^a,f   Cicero, Simona ^b   Janga, Deepa ^c   Singh, Mandeep ^g   Molina, Francisca S ^j   Persico, Nicola ^l   Jani, Jacques C ^m   Plasencia, Walter ^k   Papaioannou, George ⁿ   Tenenbaum Gavish, Kinneret ^o   Meiri, Hamutal ^p   Gizurarson, Sveinbjorn ^q   Maclagan, Kate ^d   Nicolaides, Kypros H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^c NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF EXETER   (United Kingdom)

^f MEDWAY MARITIME HOSPITAL   (United Kingdom)

^g SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^j HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^k Grupo Hospiten   (Spain)

^l FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^m BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

ⁿ NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^o RABIN MEDICAL CENTER   (Israel)

^p HY LABORATORIES LTD   (Israel)

^q UNIVERSITY OF ICELAND   (Iceland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ADULT; ADVERSE OUTCOME; ANEMIA; ARTICLE; BACTEREMIA; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GESTATION PERIOD; GROWTH RETARDATION; HIGH RISK PATIENT; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFORMED CONSENT; INTENSIVE CARE UNIT; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MATERNAL HYPERTENSION; MULTICENTER STUDY; NECROTIZING ENTEROCOLITIS; PATIENT COMPLIANCE; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RISK REDUCTION; SENSITIVITY ANALYSIS; SEPSIS; SIDE EFFECT; SMALL FOR DATE INFANT; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; SPONTANEOUS PLACENTAL DELIVERY; STILLBIRTH; TREATMENT DURATION; CLINICAL TRIAL; COMPARATIVE STUDY; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; NEWBORN; PRE-ECLAMPSIA; PREGNANCY; RISK;

ADULT; ASPIRIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RISK;

EID: 85027479824     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1704559     Document Type: Article

References (26)

1. Duley L. The global impact of preeclampsia and eclampsia. Semin Perinatol 2009;33:130-7.
2. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 2013;209(6): 544.e1-544.e12.
3. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001;323:1213-7.
4. Yu CK, Khouri O, Onwudiwe N, Spiliopoulos Y, Nicolaides KH. Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008;31: 310-3.
5. Crandon AJ, Isherwood DM. Effect of aspirin on incidence of pre-eclampsia. Lancet 1979;1:1356.
6. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369:1791-8.
7. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2017; 216(2):121-128.e2.
8. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402-14.
9. Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013;41:491-9.
10. Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017;216(2):110-120.e6.
11. National Collaborating Centre for Women’s and Children’s Health (UK). Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: RCOG Press, 2010.
12. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 2015;213(1): 62.e1-62.e10.
13. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122:1122-31.
14. O’Gorman N, Wright D, Poon LC, et al. Multicenter screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation: comparison to NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol 2017;49:756-60.
15. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013;33:8-15.
16. Robinson HP, Fleming JE. A critical evaluation of sonar “crown-rump length” measurements. Br J Obstet Gynaecol 1975; 82:702-10.
17. Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH. Protocol for measurement of mean arterial pressure at 11-13 weeks’ gestation. Fetal Diagn Ther 2012;31:42-8.
18. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007;30:742-9.
19. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20(1): IX-XIV.
20. Poon LC, Tan MY, Yerlikaya G, Syngelaki A, Nicolaides KH. Birth weight in live births and stillbirths. Ultrasound Obstet Gynecol 2016;48:602-6.
21. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2011 (http://www.R-project.org/).
22. Van Buuren S, Groothuis-Oudshoorn K. Multivariate imputation by chained equations in R. J Stat Softw 2011;45:1-67.
23. O’Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol 2016;214(1):103.e1-103.e12.
24. Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31: 141-6.
25. Caron N, Rivard GE, Michon N, et al. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. J Obstet Gynaecol Can 2009;31:1022-7.
26. Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013;30:260-79.